Johnson & Johnson Vision,* a global leader in eye health and part of Johnson & Johnson MedTech,** today announced it has received U.S. Food & Drug Administration (FDA) clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens innovation, ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL. The announcement comes during the 125th Annual AOA Congress and 54th Annual AOSA Conference: Optometry’s Meeting® 2022 in Chicago (June 15-18).